Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Blood hemostasis
- Activation of procoagulant factors by injury
- Anticoagulant factors
- The role of antithrombin and heparan sulfate
- Antithrombin
- Inherited deficiencies of antithrombin
- Mutations causing antithrombin dysfunction
- Serpins: proteolytic enzymes regulators
- Serpins characteristics
- Lock-and-key vs.serpin type protease inhibitors
- Serpin type protease inhibitors structure
- Inhibition mechanism through antithrombin activity
- Heparin/heparan sulfate structure
- Activation of antithrombin
- X-ray structure of the antithrombin-heparin complex
- Close-up of the heparin binding site of antithrombin
- Antithrombin "hotspots" binding heparin
- Heparin binds antithrombin in a two-step process
- Antithrombin hotspots contribute to heparin binding
- Effect of saccharides: antithrombin-heparin affinity
- The induced-conformational change binding
- Pre-equilibrium binding mechanism
- Allosteric activation of antithrombin by heparin
- Effect of heparin on antithrombin reactivity
- Activation mechanisms of antithrombin by heparin
- The bridging mechanism
- The conformational activation mechanism (1)
- The conformational activation mechanism (2)
- Hypothesis: reactivity enhancment by reactive loop
- Results of the hypothesis tested
- Modified conformational activation mechanism
- Mapping the antithrombin exosite (1)
- Mapping the antithrombin exosite (2)
- Localization of the exosite of antithrombin
- Two residues mutants affect antithrombin reactivity
- Antithrombin/heparin/FXa complexes structures
- Heparin activation of antithrombin: summary
- Conserved residues in the reactive loop sequences
- Limited reactivity of serpin by the AT reactive loop
- Molecular basis for antithrombin selective reactivity
- Negative features of heparin anticoagulant thepray
- Reference (1)
- Reference (2)
- Reference (3)
Topics Covered
- Antithrombin and hemostasis
- Dysfunctional antithrombins and thrombophilia
- Protease regulation by serpins
- Heparin requirement for antithrombin function
- Structural determinants of heparin binding to antithrombin
- Heparin-induced conformational changes in antithrombin
- Heparin as an allosteric activator of antithrombin
- Bridging and conformational change mechanisms of heparin activation of antithrombin
- Structural basis of conformational activation
- Role of exosites in conformational activation
- Role of the reactive loop in antithrombin anticoagulant function
- Implications for improved heparin anticoagulants
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Olson, S. (2007, October 1). Regulation of blood coagulation by the serpin, antithrombin [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/VLVT7240.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Steve Olson has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.